Disruptions in this balance, such as through mutations in INTS6 or INTS11, lead to aberrant transcriptional elongation, resistance to CDK9 inhibition, and amplified oncogenic transcriptional responses, linking the INTS complex to both transcriptional regulation and tumor susceptibility (33, 38). The gene discussed is CDK9; the disease is neoplasm.